TY - JOUR
T1 - Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro
AU - Coffey, Dennis C.
AU - Kutko, Martha C.
AU - Glick, Richard D.
AU - Swendeman, Steven L.
AU - Butler, Lisa
AU - Rifkind, Richard
AU - Marks, Paul A.
AU - Richon, Victoria M.
AU - LaQuaglia, Michael P.
PY - 2000
Y1 - 2000
N2 - Background. Neuroblastoma is a common childhood cancer with a poor overall prognosis. Retinoic acids (RAs) have been studied as a potential therapy, showing promise in recurrent disease. The histone deacetylase inhibitor (HDACI) M-carboxycinnamic acid bishydroxamide (CBHA) is another potential therapy, which we recently described. Combinations of RAs and HDACIs currently under investigation display synergy in certain neoplasms. In this study, we evaluate the effect of combinations of RAs and HDACIs on human neuroblastoma cells. Procedure. Established cell lines were cultured in increasing concentrations of HDA-CIs, RAs, and combinations thereof. Following exposure, viable cell number was quantified by trypan blue dye exclusion on a hemacytometer. Cell cycle analysis was performed by propidium iodide staining and FACS. Results. All assayed HDACIs and RAs decreased viable cell number. Lower concentrations of each agent were effective when the two were combined. The primary reason for decreased cell number appears to be apoptosis following HDACI exposure and G1 arrest following RA exposure. Both effects are seen with cotreatment. Caspase inhibition abrogates the apoptotic response. Conclusions. CBHA causes apoptosis of human neuroblastoma in vitro, an effect that can add to the effects of RA. HDACIs and RAs inhibit neuroblastoma in significantly lower concentrations when used together than when used individually. Combination therapy may improve the ultimate efficacy while reducing the side effects of these agents in clinical use. (C) 2000 Wiley-Liss, Inc.
AB - Background. Neuroblastoma is a common childhood cancer with a poor overall prognosis. Retinoic acids (RAs) have been studied as a potential therapy, showing promise in recurrent disease. The histone deacetylase inhibitor (HDACI) M-carboxycinnamic acid bishydroxamide (CBHA) is another potential therapy, which we recently described. Combinations of RAs and HDACIs currently under investigation display synergy in certain neoplasms. In this study, we evaluate the effect of combinations of RAs and HDACIs on human neuroblastoma cells. Procedure. Established cell lines were cultured in increasing concentrations of HDA-CIs, RAs, and combinations thereof. Following exposure, viable cell number was quantified by trypan blue dye exclusion on a hemacytometer. Cell cycle analysis was performed by propidium iodide staining and FACS. Results. All assayed HDACIs and RAs decreased viable cell number. Lower concentrations of each agent were effective when the two were combined. The primary reason for decreased cell number appears to be apoptosis following HDACI exposure and G1 arrest following RA exposure. Both effects are seen with cotreatment. Caspase inhibition abrogates the apoptotic response. Conclusions. CBHA causes apoptosis of human neuroblastoma in vitro, an effect that can add to the effects of RA. HDACIs and RAs inhibit neuroblastoma in significantly lower concentrations when used together than when used individually. Combination therapy may improve the ultimate efficacy while reducing the side effects of these agents in clinical use. (C) 2000 Wiley-Liss, Inc.
KW - Histone deacetylase inhibitors
KW - Neuroblastoma
KW - Retinoic acids
UR - http://www.scopus.com/inward/record.url?scp=0033646839&partnerID=8YFLogxK
U2 - 10.1002/1096-911X(20001201)35:6<577::AID-MPO18>3.0.CO;2-3
DO - 10.1002/1096-911X(20001201)35:6<577::AID-MPO18>3.0.CO;2-3
M3 - Article
C2 - 11107121
AN - SCOPUS:0033646839
SN - 0098-1532
VL - 35
SP - 577
EP - 581
JO - Medical and Pediatric Oncology
JF - Medical and Pediatric Oncology
IS - 6
ER -